|
Kim,
There are a number of persons reading this website eager to learn of anything new in trials for those her2neu+ and er+/pr+ or er+/pr-. Reviewing the literature, these make up anywhere from 10% of her2neu tumors (what is usually quoted) to 44% or so of her2neu tumors. Chemotherapy is not so effective in them and may serve mostly to put them into menopause, if they are not already there. Being her2positive, tamoxifen tends to be ineffective in them and even early studies on ais shows them to perhaps need concommitant herceptin treatment for ai efficacy to be enhanced (this appears to be less effective in er+/pr+than er+/pr- patients per the her2 therapy article by Edith Perez recently posted on this site.
Since your company owns Genentech, perhaps someone you know could find out what clinical trials are in the pipeline besides the E75 HER2 VACCINE (we hope) combining herceptiin with agents other than anthracyclines (adriamycin, epirubicin, etc) , taxols, and cisplatin IN THE ADJUVANT SETTING.
As there are elderly, frail and cardiac-compromised patinets in whom the above treatments are contraindicated, such a trial is sorely needed!
Let's hope you can "pick their brains" and come back with some hopeful news!
Best of luck with your treatment,
Lani
|